國立高雄大學圖資館 |

Drug discovery and evaluationsafety and pharmacokinetic assays /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Drug discovery and evaluationedited by Franz J. Hock, Michael K. Pugsley.
其他題名:	safety and pharmacokinetic assays /
其他作者:	Hock, Franz J.
出版者:	Cham :Springer International Publishing :2024.
面頁冊數:	xxxiii, 2777 p. :ill., digital ;24 cm.
Contained By:	Springer Nature eReference
標題:	Drug development.
電子資源:	https://doi.org/10.1007/978-3-031-35529-5
ISBN:	9783031355295$q(electronic bk.)

Drug discovery and evaluationsafety and pharmacokinetic assays /
Drug discovery and evaluationsafety and pharmacokinetic assays /[electronic resource] :edited by Franz J. Hock, Michael K. Pugsley. - Third edition. - Cham :Springer International Publishing :2024. - xxxiii, 2777 p. :ill., digital ;24 cm.

Preface -- Part 1 Safety Pharmacology -- Part 2 Safety Pharmacokinetics -- Part 3 Safety Toxicology.

Many aspects of drug safety have become an outstanding and even persistent issue and may occur during the process of both drug discovery and development. Until 15 years ago, drug discovery and evaluation was primarily a sequential process starting with the selection of the most pharmacologically active compound from a series of newly synthesized small molecule chemical series by means of distinctive pharmacological assays. Safety aspects were addressed by evaluation of the selected compound at high doses in a series of specific studies directed at indications other than the intended indication of the new compound. These tests are then followed by pharmacokinetic studies, which are primarily conducted to confirm whether the selected compound possesses a suitable half-life for sufficient exposure and efficacy and, whether it has the desired properties specificity to the intended route of administration. Safety aspects relied predominantly on the conduct of single and repeat toxicologydose studies, which inform changes in organ structure rather than organ function. Both toxicological and pharmacokinetic studies are adapted to the progress of studies in clinical pharmacology and clinical trials. The new edition of this well and broadly accepted reference work contains several innovative and distinguished chapters. This "sequential" strategy has been abandoned with this new version of the book for several reasons: - Of the possible multitude of negative effects that novel drugs may impart on organ function, e.g. ventricular tachy-arrhythmia, many are detected too late in non-clinical studies to inform clinicians. On the other hand, negative findings in chronic toxicity studies in animals may turn out to be irrelevant for human beings. - New scientific approaches, e.g. high-throughput screening, human pluripotent stem cells, transgenic animals, knock-out animals, in silico models, pharmaco-genomics and pharmaco-proteomics, as well as Artificial Intelligence (AI) methods offered new possibilities. - There are several examples, that show that the "druggability" of compounds was considerably underestimated when the probability of success of a new project was assessed. The success rate in the pharmaceutical industry and the introduction of new chemical entities to the market per year dropped dramatically, whereas the development time for a new compound increased, sometimes exceeding the patent protection. Research and development scientists, involving the following changes, therefore adopted a change of strategy: - Parallel instead of sequential involvement of the various disciplines (multidimensional compound optimization) - The term "Safety Pharmacology" was coined. The International Conference on Harmonization (ICH) founded a Safety Pharmacology Working Group and the Safety Pharmacology Society (SPS) was launched. The discipline provided for evaluation, development and validation of a multitude of safety tests outlined in the 'Core Battery of Studies'. - Characterizing the exposure profile of a drug by conducting pharmacokinetic studies that evaluates the absorption, distribution, metabolism and excretion should to be investigated at an early stage of development as results contribute to the selection of a compound for further development. Advancements in Toxicology were achieved by the introduction of new methods, e.g., in silico methods, genetic toxicology, computational toxicology and AI. The book is a landmark in the continuously changing world of drug research and developments. As such, it is essential reading for many groups: not only for all students of pharmacology and toxicology but also for industry scientists and physicians, especially those involved in clinical trials of drugs, and for pharmacists who must know the safety requirements of drugs. The book is essential for scientists and managers in the pharmaceutical industry who are involved in drug discovery, drug development and decision making in the development process. In particular, the book will be of use to government institutions and committees working on official guidelines for drug evaluation worldwide.

ISBN: 9783031355295$q(electronic bk.)

Standard No.: 10.1007/978-3-031-35529-5doiSubjects--Topical Terms:

190608
Drug development.

LC Class. No.: RS420

Dewey Class. No.: 615.19

Drug discovery and evaluationsafety and pharmacokinetic assays /
LDR:05378nmm a2200349 a 4500 001 671113
003 DE-He213
005 20241022125743.0
006 m d
007 cr nn 008maaau
008 250325s2024 sz s 0 eng d
020 $a 9783031355295$q(electronic bk.)
020 $a 9783031355288$q(paper)
024 7 $a 10.1007/978-3-031-35529-5 $2 doi
035 $a 978-3-031-35529-5
040 $a GP $c GP
041 0 $a eng
050 4 $a RS420
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
072 7 $a MKG $2 thema
082 0 4 $a 615.19 $2 23
090 $a RS420 $b .D794 2024
245 0 0 $a Drug discovery and evaluation $h [electronic resource] : $b safety and pharmacokinetic assays / $c edited by Franz J. Hock, Michael K. Pugsley.
250 $a Third edition.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2024.
300 $a xxxiii, 2777 p. : $b ill., digital ; $c 24 cm.
505 0 $a Preface -- Part 1 Safety Pharmacology -- Part 2 Safety Pharmacokinetics -- Part 3 Safety Toxicology.
520 $a Many aspects of drug safety have become an outstanding and even persistent issue and may occur during the process of both drug discovery and development. Until 15 years ago, drug discovery and evaluation was primarily a sequential process starting with the selection of the most pharmacologically active compound from a series of newly synthesized small molecule chemical series by means of distinctive pharmacological assays. Safety aspects were addressed by evaluation of the selected compound at high doses in a series of specific studies directed at indications other than the intended indication of the new compound. These tests are then followed by pharmacokinetic studies, which are primarily conducted to confirm whether the selected compound possesses a suitable half-life for sufficient exposure and efficacy and, whether it has the desired properties specificity to the intended route of administration. Safety aspects relied predominantly on the conduct of single and repeat toxicologydose studies, which inform changes in organ structure rather than organ function. Both toxicological and pharmacokinetic studies are adapted to the progress of studies in clinical pharmacology and clinical trials. The new edition of this well and broadly accepted reference work contains several innovative and distinguished chapters. This "sequential" strategy has been abandoned with this new version of the book for several reasons: - Of the possible multitude of negative effects that novel drugs may impart on organ function, e.g. ventricular tachy-arrhythmia, many are detected too late in non-clinical studies to inform clinicians. On the other hand, negative findings in chronic toxicity studies in animals may turn out to be irrelevant for human beings. - New scientific approaches, e.g. high-throughput screening, human pluripotent stem cells, transgenic animals, knock-out animals, in silico models, pharmaco-genomics and pharmaco-proteomics, as well as Artificial Intelligence (AI) methods offered new possibilities. - There are several examples, that show that the "druggability" of compounds was considerably underestimated when the probability of success of a new project was assessed. The success rate in the pharmaceutical industry and the introduction of new chemical entities to the market per year dropped dramatically, whereas the development time for a new compound increased, sometimes exceeding the patent protection. Research and development scientists, involving the following changes, therefore adopted a change of strategy: - Parallel instead of sequential involvement of the various disciplines (multidimensional compound optimization) - The term "Safety Pharmacology" was coined. The International Conference on Harmonization (ICH) founded a Safety Pharmacology Working Group and the Safety Pharmacology Society (SPS) was launched. The discipline provided for evaluation, development and validation of a multitude of safety tests outlined in the 'Core Battery of Studies'. - Characterizing the exposure profile of a drug by conducting pharmacokinetic studies that evaluates the absorption, distribution, metabolism and excretion should to be investigated at an early stage of development as results contribute to the selection of a compound for further development. Advancements in Toxicology were achieved by the introduction of new methods, e.g., in silico methods, genetic toxicology, computational toxicology and AI. The book is a landmark in the continuously changing world of drug research and developments. As such, it is essential reading for many groups: not only for all students of pharmacology and toxicology but also for industry scientists and physicians, especially those involved in clinical trials of drugs, and for pharmacists who must know the safety requirements of drugs. The book is essential for scientists and managers in the pharmaceutical industry who are involved in drug discovery, drug development and decision making in the development process. In particular, the book will be of use to government institutions and committees working on official guidelines for drug evaluation worldwide.
650 0 $a Drug development. $3 190608
650 0 $a Drugs $x Testing. $3 183737
650 1 4 $a Pharmacology. $3 218135
650 2 4 $a Pharmaceutics. $3 913065
650 2 4 $a Medicinal Chemistry. $3 275183
700 1 $a Hock, Franz J. $3 737073
700 1 $a Pugsley, Michael K. $3 726253
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer Nature eReference
856 4 0 $u https://doi.org/10.1007/978-3-031-35529-5
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Reference Module Biomedical and Life Sciences (SpringerNature-43744)